Matthew R. Smith
Massachusetts General Hospital Cancer Center
Yawkey 7030
55 Fruit St
Boston
Name/email consistency: high
- Sarcopenia during androgen-deprivation therapy for prostate cancer. Smith, M.R., Saad, F., Egerdie, B., Sieber, P.R., Tammela, T.L., Ke, C., Leder, B.Z., Goessl, C. J. Clin. Oncol. (2012)
- Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Smith, M.R., Saad, F., Coleman, R., Shore, N., Fizazi, K., Tombal, B., Miller, K., Sieber, P., Karsh, L., Damião, R., Tammela, T.L., Egerdie, B., Van Poppel, H., Chin, J., Morote, J., Gómez-Veiga, F., Borkowski, T., Ye, Z., Kupic, A., Dansey, R., Goessl, C. Lancet (2012)
- Denosumab and changes in bone turnover markers during androgen deprivation therapy for prostate cancer. Smith, M.R., Saad, F., Egerdie, B., Sieber, P., Tammela, T., Leder, B.Z., Ke, C., Goessl, C. J. Bone Miner. Res. (2011)
- Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer. Smith, M.R., Cook, R., Lee, K.A., Nelson, J.B. Cancer (2011)
- Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. Smith, M.R., Morton, R.A., Barnette, K.G., Sieber, P.R., Malkowicz, S.B., Rodriguez, D., Hancock, M.L., Steiner, M.S. J. Urol. (2010)
- Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer. Smith, M.R., Saad, F., Egerdie, B., Szwedowski, M., Tammela, T.L., Ke, C., Leder, B.Z., Goessl, C. J. Urol. (2009)
- Denosumab in men receiving androgen-deprivation therapy for prostate cancer. Smith, M.R., Egerdie, B., Hernández Toriz, N., Feldman, R., Tammela, T.L., Saad, F., Heracek, J., Szwedowski, M., Ke, C., Kupic, A., Leder, B.Z., Goessl, C. N. Engl. J. Med. (2009)
- Diabetes and mortality in men with locally advanced prostate cancer: RTOG 92-02. Smith, M.R., Bae, K., Efstathiou, J.A., Hanks, G.E., Pilepich, M.V., Sandler, H.M., Shipley, W.U. J. Clin. Oncol. (2008)
- Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study. Smith, M.R., Malkowicz, S.B., Chu, F., Forrest, J., Price, D., Sieber, P., Barnette, K.G., Rodriguez, D., Steiner, M.S. J. Urol. (2008)
- Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome. Smith, M.R., Lee, H., McGovern, F., Fallon, M.A., Goode, M., Zietman, A.L., Finkelstein, J.S. Cancer (2008)
- Toremifene improves lipid profiles in men receiving androgen-deprivation therapy for prostate cancer: interim analysis of a multicenter phase III study. Smith, M.R., Malkowicz, S.B., Chu, F., Forrest, J., Sieber, P., Barnette, K.G., Rodriquez, D., Steiner, M.S. J. Clin. Oncol. (2008)
- Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer. Smith, M.R., Lee, H., Fallon, M.A., Nathan, D.M. Urology (2008)
- Gonadotrophin-releasing hormone agonists, diabetes and cardiovascular disease in men with prostate cancer: which metabolic syndrome?. Smith, M.R., O'Malley, A.J., Keating, N.L. BJU Int. (2008)
- Osteoclast targeted therapy for prostate cancer: bisphosphonates and beyond. Smith, M.R. Urol. Oncol. (2008)
- Androgen deprivation therapy and risk for diabetes and cardiovascular disease in prostate cancer survivors. Smith, M.R. Curr. Urol. Rep (2008)
- Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancer. Smith, M.R., Cook, R.J., Coleman, R., Brown, J., Lipton, A., Major, P., Hei, Y.J., Saad, F. Urology (2007)
- Androgen deprivation therapy for prostate cancer: new concepts and concerns. Smith, M.R. Curr. Opin. Endocrinol. Diabetes. Obes (2007)
- Obesity and sex steroids during gonadotropin-releasing hormone agonist treatment for prostate cancer. Smith, M.R. Clin. Cancer Res. (2007)
- Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer. Smith, M.R., Boyce, S.P., Moyneur, E., Duh, M.S., Raut, M.K., Brandman, J. J. Urol. (2006)
- Insulin sensitivity during combined androgen blockade for prostate cancer. Smith, M.R., Lee, H., Nathan, D.M. J. Clin. Endocrinol. Metab. (2006)
- Markers of bone metabolism in prostate cancer. Smith, M.R. Cancer Treat. Rev. (2006)
- Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy. Smith, M.R., Manola, J., Kaufman, D.S., Oh, W.K., Bubley, G.J., Kantoff, P.W. J. Clin. Oncol. (2006)
- Treatment-related osteoporosis in men with prostate cancer. Smith, M.R. Clin. Cancer Res. (2006)
- Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. Smith, M.R., Kabbinavar, F., Saad, F., Hussain, A., Gittelman, M.C., Bilhartz, D.L., Wynne, C., Murray, R., Zinner, N.R., Schulman, C., Linnartz, R., Zheng, M., Goessl, C., Hei, Y.J., Small, E.J., Cook, R., Higano, C.S. J. Clin. Oncol. (2005)
- Zoledronic acid to prevent skeletal complications in cancer: corroborating the evidence. Smith, M.R. Cancer Treat. Rev. (2005)
- Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. Smith, M.R., Lee, W.C., Brandman, J., Wang, Q., Botteman, M., Pashos, C.L. J. Clin. Oncol. (2005)
- Therapy Insight: osteoporosis during hormone therapy for prostate cancer. Smith, M.R. Nature Clinical Practice. Urology (2005)
- The role of bisphosphonates in men with prostate cancer receiving androgen deprivation therapy. Smith, M.R. Oncology (Williston Park, N.Y.) (2004)
- Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. Smith, M.R., Goode, M., Zietman, A.L., McGovern, F.J., Lee, H., Finkelstein, J.S. J. Clin. Oncol. (2004)
- Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. Smith, M.R., Fallon, M.A., Lee, H., Finkelstein, J.S. J. Clin. Endocrinol. Metab. (2004)
- Osteoclast-targeted therapy for prostate cancer. Smith, M.R. Curr. Treat. Options. Oncol (2004)
- Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy. Smith, M.R., Manola, J., Kaufman, D.S., George, D., Oh, W.K., Mueller, E., Slovin, S., Spiegelman, B., Small, E., Kantoff, P.W. Cancer (2004)
- Osteoporosis and obesity in men receiving hormone therapy for prostate cancer. Smith, M.R. J. Urol. (2004)
- Diagnosis and management of treatment-related osteoporosis in men with prostate carcinoma. Smith, M.R. Cancer (2003)
- Management of treatment-related osteoporosis in men with prostate cancer. Smith, M.R. Cancer Treat. Rev. (2003)
- Bisphosphonates to prevent skeletal complications in men with metastatic prostate cancer. Smith, M.R. J. Urol. (2003)
- Changes in body composition during hormonal therapy for prostate cancer. Smith, M.R. Clin. Prostate. Cancer (2003)
- Changes in body composition during androgen deprivation therapy for prostate cancer. Smith, M.R., Finkelstein, J.S., McGovern, F.J., Zietman, A.L., Fallon, M.A., Schoenfeld, D.A., Kantoff, P.W. J. Clin. Endocrinol. Metab. (2002)
- Measurement of body fat by dual-energy X-ray absorptiometry and bioimpedance analysis in men with prostate cancer. Smith, M.R., Fuchs, V., Anderson, E.J., Fallon, M.A., Manola, J. Nutrition (2002)
- Peroxisome proliferator-activated receptor gamma (PPargamma) as a novel target for prostate cancer. Smith, M.R., Kantoff, P.W. Invest. New. Drugs (2002)
- Osteoporosis during androgen deprivation therapy for prostate cancer. Smith, M.R. Urology (2002)
- Selective aromatase inhibition for patients with androgen-independent prostate carcinoma. Smith, M.R., Kaufman, D., George, D., Oh, W.K., Kazanis, M., Manola, J., Kantoff, P.W. Cancer (2002)
- Osteoporosis and other adverse body composition changes during androgen deprivation therapy for prostate cancer. Smith, M.R. Cancer Metastasis Rev. (2002)
- Low bone mineral density in hormone-naïve men with prostate carcinoma. Smith, M.R., McGovern, F.J., Fallon, M.A., Schoenfeld, D., Kantoff, P.W., Finkelstein, J.S. Cancer (2001)
- Complementary and alternative therapies for advanced prostate cancer. Smith, M.R. Hematol. Oncol. Clin. North Am. (2001)
- Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. Smith, M.R., McGovern, F.J., Zietman, A.L., Fallon, M.A., Hayden, D.L., Schoenfeld, D.A., Kantoff, P.W., Finkelstein, J.S. N. Engl. J. Med. (2001)
- Vinorelbine and estramustine in androgen-independent metastatic prostate cancer: a phase II study. Smith, M.R., Kaufman, D., Oh, W., Guerin, K., Seiden, M., Makatsoris, T., Manola, J., Kantoff, P.W. Cancer (2000)